Cas:2883-45-6 1,6-heptadien-4-ol manufacturer & supplier

We serve Chemical Name:1,6-heptadien-4-ol CAS:2883-45-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,6-heptadien-4-ol

Chemical Name:1,6-heptadien-4-ol
CAS.NO:2883-45-6
Synonyms:diallylmethanol;4-hepta-1,6-dienol;EINECS 220-742-0;4-hydroxyhepta-1,6-diene;heptadienol;1,6-heptadiene-4-ol;diallyl carbinol;MFCD00008663;1,6-Heptadien-4-ol
Molecular Formula:C7H12O
Molecular Weight:112.17000
HS Code:2905290000

Physical and Chemical Properties:
Melting point:N/A
Boiling point:151 °C(lit.)
Density:0.864 g/mL at 25 °C(lit.)
Index of Refraction:n20/D 1.45(lit.)
PSA:20.23000
Exact Mass:112.08900
LogP:1.49950

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1987 3/PG 3
Packing Group:III


Contact us for information like diallylmethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,6-Heptadien-4-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,diallyl carbinol Use and application,1,6-heptadiene-4-ol technical grade,usp/ep/jp grade.


Related News: Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 1,6-heptadien-4-ol manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 1,6-heptadien-4-ol supplier Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. 1,6-heptadien-4-ol vendor Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies. 1,6-heptadien-4-ol factory In October 2020, the Trump administration ordered $375 million worth of Lilly’s COVID-19 antibody therapy bamlanivimab, which is manufactured at the Branchburg plant.